NovoCure Files 8-K: Routine Corporate Update, Non-EGC Status Confirmed

TL;DR

**NovoCure filed a routine 8-K, confirming corporate details and non-emerging growth company status.**

AI Summary

NovoCure Ltd. filed an 8-K on January 18, 2024, primarily to disclose general corporate information and confirm its status as a non-emerging growth company. The filing, under Accession Number 0001645113-24-000005, updates basic company details like its address at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, and its trading symbol NVCR on The Nasdaq Stock Market LLC. This matters to investors because it provides routine administrative updates, confirming the company's compliance with SEC regulations and its established position in the market, which can be reassuring for current and potential shareholders.

Why It Matters

This filing provides standard administrative updates, confirming NovoCure's compliance with SEC regulations and its established market position, which can offer reassurance to investors.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing with no material financial or operational disclosures that would introduce new risks.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes to the company's operations or financial health, and would not base investment decisions solely on this administrative update.

Key Players & Entities

• NovoCure Ltd (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where NovoCure's Ordinary Shares are registered
• NVCR (company) — NovoCure's trading symbol
• January 18, 2024 (date) — date of earliest event reported and filing date
• 001-37565 (dollar_amount) — Commission File Number
• No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (company) — NovoCure's principal executive offices address

FAQ

Filing Documents

• nvcr-20240118.htm (8-K) — 25KB
• lunarfdafilingacceptancepr.htm (EX-99.1) — 11KB
• 0001645113-24-000005.txt ( ) — 163KB
• nvcr-20240118.xsd (EX-101.SCH) — 2KB
• nvcr-20240118_lab.xml (EX-101.LAB) — 23KB
• nvcr-20240118_pre.xml (EX-101.PRE) — 12KB
• nvcr-20240118_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 18, 2024, NovoCure Limited issued a press re lease announcing that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration. A copy of the press rel ease is attached hereto as Exhibit 99.1. The information contained in item 7.01 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated January 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: January 18, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR